Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 13,402,000 | 4,173,000 | 2,527,000 | 1,225,000 | 5,723,000 |
| Depreciation Amortization | 3,218,000 | 2,411,000 | 1,610,000 | 805,000 | 3,243,000 |
| Accounts receivable | -691,000 | -533,000 | -476,000 | -151,000 | -356,000 |
| Other Working Capital | -9,217,000 | -826,000 | -989,000 | -561,000 | -2,475,000 |
| Other Operating Activity | 1,846,000 | 465,000 | 313,000 | -293,000 | 1,126,000 |
| Operating Cash Flow | $8,558,000 | $5,690,000 | $2,985,000 | $1,025,000 | $7,261,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 9,000 | 49,000 | -28,000 | N/A |
| PPE Investments | -2,207,000 | -1,487,000 | -931,000 | -398,000 | -2,202,000 |
| Net Acquisitions | 1,000 | 1,000 | 1,000 | N/A | -837,000 |
| Purchase Of Investment | -169,000 | N/A | N/A | N/A | -159,000 |
| Sale Of Investment | 28,000 | N/A | N/A | N/A | 43,000 |
| Other Investing Activity | 9,000 | 5,000 | 3,000 | 1,000 | 22,000 |
| Investing Cash Flow | $-2,338,000 | $-1,472,000 | $-878,000 | $-425,000 | $-3,133,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -100,000 | -126,000 | -170,000 | -127,000 | 21,000 |
| Debt Issued | 223,000 | 222,000 | 221,000 | 0 | 2,000 |
| Debt Repayment | -660,000 | -20,000 | -18,000 | 0 | -2,498,000 |
| Common Stock Issued | 264,000 | 239,000 | 147,000 | 134,000 | 167,000 |
| Common Stock Repurchased | -1,295,000 | -980,000 | -229,000 | -226,000 | -1,227,000 |
| Dividend Paid | -3,836,000 | -2,878,000 | -1,918,000 | -957,000 | -3,556,000 |
| Financing Cash Flow | $-5,404,000 | $-3,543,000 | $-1,967,000 | $-1,176,000 | $-7,091,000 |
| Exchange Rate Effect | -96,000 | -13,000 | -49,000 | -36,000 | -23,000 |
| Beginning Cash Position | 6,896,000 | 6,896,000 | 6,896,000 | 6,896,000 | 9,882,000 |
| End Cash Position | 7,616,000 | 7,558,000 | 6,987,000 | 6,284,000 | 6,896,000 |
| Net Cash Flow | $720,000 | $662,000 | $91,000 | $-612,000 | $-2,986,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,558,000 | 5,690,000 | 2,985,000 | 1,025,000 | 7,261,000 |
| Capital Expenditure | -2,207,000 | -1,487,000 | -931,000 | -398,000 | -2,202,000 |
| Free Cash Flow | 6,351,000 | 4,203,000 | 2,054,000 | 627,000 | 5,059,000 |